0000880771-16-000177.txt : 20160816
0000880771-16-000177.hdr.sgml : 20160816
20160816173206
ACCESSION NUMBER: 0000880771-16-000177
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160812
FILED AS OF DATE: 20160816
DATE AS OF CHANGE: 20160816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meng Chuncai
CENTRAL INDEX KEY: 0001600522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 161836950
MAIL ADDRESS:
STREET 1: 30F SHANGHAI TIMES SQUARE
STREET 2: NO. 93 HUAI HAI ROAD
CITY: SHANGHAI
STATE: F4
ZIP: 200021
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2016-08-12
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001600522
Meng Chuncai
950 TOWER LANE, SUITE 200
FOSTER CITY
CA
94404
0
1
0
0
Gen. Counsel & VP Compliance
Common Stock
2016-08-12
4
M
0
23333
4.52
A
23333
D
Common Stock
2016-08-12
4
S
0
23333
10.41
D
0
D
Common Stock
2016-08-12
4
M
0
7000
8.83
A
7000
D
Common Stock
2016-08-12
4
S
0
7000
10.41
D
0
D
Common Stock
2016-08-12
4
M
0
750
0
A
750
D
Common Stock
2016-08-12
4
S
0
750
10.41
D
0
D
Non-Qualified Stock Options (right to buy)
4.52
2016-08-12
4
M
0
23333
0
D
2024-03-14
Common Stock
23333
30000
D
Non-Qualified Stock Options (right to buy)
8.83
2016-08-12
4
M
0
7000
0
D
2025-03-16
Common Stock
7000
14000
D
Restricted Stock Unit
2016-08-12
4
M
0
750
0
D
Common Stock
750
5250
D
Granted under the Issuer's 2005 Equity Incentive Plan.
25% of such shares vest on February 9, 2015 and 2.0833% vests each month thereafter provided that the Reporting Person continues to be employed by the Issuer.
25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
/s/ Friedhelm Blobel, Attorney-in-Fact For Chuncai Meng
2016-08-16